Cantargia Gestion

Gestion contrôle des critères 1/4

Le PDG Cantargia est Goran Forsberg, nommé en Jun2014, a un mandat de 9.42 ans. La rémunération annuelle totale est SEK 5.07M, composée du salaire de 45.1% et des bonus 54.9%, y compris les actions et options de la société. détient directement 0.13% des actions de la société, d'une valeur de SEK 942.79K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.9 ans et 3.1 ans.

Informations clés

Goran Forsberg

Directeur général

SEK 5.1m

Rémunération totale

Pourcentage du salaire du PDG	45.1%
Durée du mandat du directeur général	9.4yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	1.9yrs
Durée moyenne du mandat des membres du conseil d'administration	3.1yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Goran Forsberg a-t-elle évolué par rapport aux bénéfices de Cantargia?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2023	n/a	n/a	-SEK 299m
Jun 30 2023	n/a	n/a	-SEK 293m
Mar 31 2023	n/a	n/a	-SEK 330m
Dec 31 2022	SEK 5m	SEK 2m	-SEK 372m
Sep 30 2022	n/a	n/a	-SEK 385m
Jun 30 2022	n/a	n/a	-SEK 419m
Mar 31 2022	n/a	n/a	-SEK 411m
Dec 31 2021	SEK 5m	SEK 2m	-SEK 367m
Sep 30 2021	n/a	n/a	-SEK 319m
Jun 30 2021	n/a	n/a	-SEK 255m
Mar 31 2021	n/a	n/a	-SEK 206m
Dec 31 2020	SEK 6m	SEK 2m	-SEK 173m
Sep 30 2020	n/a	n/a	-SEK 153m
Jun 30 2020	n/a	n/a	-SEK 139m
Mar 31 2020	n/a	n/a	-SEK 127m
Dec 31 2019	SEK 4m	SEK 2m	-SEK 111m
Sep 30 2019	n/a	n/a	-SEK 102m
Jun 30 2019	n/a	n/a	-SEK 98m
Mar 31 2019	n/a	n/a	-SEK 101m
Dec 31 2018	SEK 3m	SEK 1m	-SEK 91m
Sep 30 2018	n/a	n/a	-SEK 78m
Jun 30 2018	n/a	n/a	-SEK 68m
Mar 31 2018	n/a	n/a	-SEK 56m
Dec 31 2017	SEK 3m	SEK 1m	-SEK 60m
Sep 30 2017	n/a	n/a	-SEK 65m
Jun 30 2017	n/a	n/a	-SEK 66m
Mar 31 2017	n/a	n/a	-SEK 58m
Dec 31 2016	SEK 3m	SEK 1m	-SEK 47m

Rémunération vs marché: La rémunération totale de Goran ($USD 485.11K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 354.22K ).

Rémunération et revenus: La rémunération de Goran a augmenté alors que l'entreprise n'est pas rentable.

PDG

Goran Forsberg (60 yo)

9.4yrs

Titularisation

SEK 5,068,000

Compensation

Mr. Goran Forsberg has been Independent Director at Guard Therapeutics International AB (publ) since May 2019. He has been the Chief Executive Officer at Cantargia AB (publ) since June 2014. Mr. Forsberg s...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Goran Forsberg	Chief Executive Officer	9.4yrs	SEK 5.07m	0.13% SEK 942.8k
Thoas Fioretos	Founder & Scientific Advisor	no data	SEK 355.00k	pas de données
Marcus Järås	Founder & Scientific Advisor	no data	pas de données	pas de données
Kjell Sjöström	Founder	no data	pas de données	pas de données
Patrik Renblad	Chief Financial Officer	less than a year	pas de données	pas de données
Liselotte Larsson	Chief Operating Officer	9.8yrs	pas de données	pas de données
David Liberg	Chief Scientific Officer	less than a year	pas de données	pas de données
Nina Valkama	Executive Assistant of Administration & Finance	1.9yrs	pas de données	pas de données
Adnan Deronic	IP & Communications Manager	1.8yrs	pas de données	pas de données
Dominique Tersago	Chief Medical Officer	1.3yrs	pas de données	pas de données
Johanna Christensen	Financial Controller	1.9yrs	pas de données	pas de données

1.9yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Gestion expérimentée: L'équipe de direction de CANTAS n'est pas considérée comme expérimentée (ancienneté moyenne 1.9 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Gunnar Magnus Severus Persson	Independent Chairman of the Board	7.8yrs	SEK 815.00k	pas de données
Damian Marron	Independent Director	2.5yrs	SEK 330.00k	pas de données
Anders Martin-Lof	Independent Director	5.5yrs	SEK 453.00k	pas de données
Magnus Nilsson	Independent Director	2.5yrs	SEK 330.00k	pas de données
Flavia Borellini	Independent Director	3.1yrs	SEK 520.00k	pas de données

3.1yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de CANTAS sont considérés comme expérimentés (ancienneté moyenne 3.1 ans).

Cantargia Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Cantargia AB (publ), Annual General Meeting, May 15, 2025

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Recent updates

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Chief Executive Officer recently bought kr140k worth of stock

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells

Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy

Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis

Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10

Cantargia AB (Publ) Announces Executive Changes

Cantargia Announces ASCO 2022 Presentation Strengthens Positive Phase IIa interim results for nadunolimab in NSCLC

Cantargia AB (publ) Presents Clinical Interim Results At ASCO 2022 Highlighting the Potential of Nadunolimab in Combination with Checkpoint Inhibitor

Cantargia AB (publ) Reports Positive Preclinical Effects in Atherosclerosis Demonstrating Potential of Can10 in Cardiovascular Disease

Forecast breakeven date pushed back to 2024

Insider recently bought kr88k worth of stock

Cantargia Reports Positive Preclinical Efficacy Data for CAN10 Demonstrating Anti-Fibrotic and Anti-Inflammatory Effects in Systemic Sclerosis

Cantargia AB (Publ) Reports Encouraging New CAN10 Toxicology Results and Schedules Phase I Trial for 2023

Cantargia AB Reports Treatment of First Non-Squamous Non-Small Cell Lung Cancer Patient in New Arm of CANFOUR Study

Cantargia Reports Positive Safety Data from Cirifour Clinical Study on Nadunolimab and Pembrolizumab Combination

Cantargia AB (Publ) Reports Treatment of First Triple Negative Breast Cancer Patient in TRIFOUR Study

Cantargia Advances Nadunolimab Against Pancreatic Cancer in the Pancan Precision Promise[Sm] Phase 2/3 Clinical Trial

Cantargia AB (publ) Reports Updated Encouraging Survival Data from CANFOUR Trial with Nadunolimab and Chemotherapy in Pancreatic Cancer

Cantargia AB (publ) Reports Positive Results for Can10 Antibody in Preclinical Systemic Sclerosis Model

Insider recently bought kr158k worth of stock

Forecast to breakeven in 2023

Cantargia AB (Publ) Announces New Positive Interim Results on Nadunolimab Combination Therapy in NSCLC Published in Abstract for the Annual ESMO Congress

Cantargia AB Completes Patient Recruitment to the Phase IIa Pancreatic Cancer Extension Cohort in the CANFOUR Study

Cantargia AB Reports Preclinical Data Highlighting Advantages of Nadunolimab Mechanism of Action